CRISPR Therapeutics stock maintains outperform rating at William Blair

William Blair reiterated its outperform rating on CRISPR Therapeutics, citing compelling Phase 1 clinical data for its CTX310 program, which demonstrated significant dose-dependent reductions of up to 86% in LDL cholesterol and 82% in triglycerides, positioning it competitively against rivals. Despite a minor delay in the CTX320 readout, the firm highlighted CRISPR's strong liquidity and strategic expansion, including a new partnership for a Factor XI siRNA therapy, suggesting its cardiovascular programs could become near-term business development targets. This reflects growing confidence in CRISPR's expanding gene-based therapy pipeline and future growth potential.

Analysis

William Blair's reiterated "outperform" rating on CRISPR Therapeutics (CRSP) is anchored by compelling Phase 1 clinical data from its CTX310 program. The cholesterol drug demonstrated significant, dose-dependent peak reductions of up to 86% in LDL cholesterol and 82% in triglycerides, positioning it as highly competitive with treatments from Arrowhead (ARWR) and Regeneron (REGN), with analysts noting the triglyceride results could establish a new benchmark. While the data readout for the CTX320 program has been delayed to the first half of 2026, William Blair views this decision favorably as a means to release a more comprehensive dataset. Financially, the company's "FAIR" health score from InvestingPro is buttressed by strong liquidity, evidenced by a current ratio of 15.6. Strategically, CRSP is expanding its pipeline through a partnership with Sirius Therapeutics for the siRNA therapy SRSD107, secured with a $25 million cash and $70 million equity upfront payment. This positive outlook, shared by Citizens JMP's "Market Outperform" rating, is further enhanced by speculation that CRSP's cardiovascular programs could become near-term acquisition targets, drawing parallels to Eli Lilly’s recent acquisition of Verve Therapeutics.

Key Decisions for Investors

• Investors should focus on the competitive strength of the CTX310 clinical data, as the significant LDL-C and triglyceride reductions position it favorably against established players and could drive future value.
• The delay of CTX320 data until H1 2026 should be monitored, as successful execution on the broader pipeline remains critical, though the company's strong liquidity mitigates near-term funding concerns.
• Consider the potential for CRSP's cardiovascular assets to become M&A targets, similar to the Eli Lilly-Verve deal, which could provide a significant, non-clinical catalyst for the stock.
• The strategic partnership with Sirius Therapeutics for SRSD107 diversifies the pipeline and validates the company's technology platform, potentially de-risking its long-term growth profile.